Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 4:10 PM ET

Biotechnology

Company Overview of Epizyme, Inc.

Company Overview

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DO...

400 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2007

86 Employees

Phone:

617-229-5872

Fax:

617-349-0707

Key Executives for Epizyme, Inc.

Chief Executive Officer, President, Secretary and Director
Age: 59
Total Annual Compensation: $652.8K
Chief Scientific Officer and President of Research
Age: 57
Total Annual Compensation: $531.7K
Chief Development Officer
Age: 52
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

Epizyme, Inc. Key Developments

Epizyme Seeks Acquisitions

Epizyme, Inc. (NasdaqGS:EPZM) intends to use the net proceeds from the sale of any securities offered under this prospectus to fund clinical development of our product candidates, to fund preclinical development and research to advance our pipeline and expand our product platform and for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, if any, working capital and capital expenditures.

Epizyme, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Epizyme, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $911,000 against $13,391,000 a year ago. Operating loss was $61,377,000 against $6,912,000 a year ago. Net loss was $61,326,000 or $1.75 per basic and diluted share against $6,884,000 or $0.22 per basic and diluted share a year ago. The decline in collaboration revenue primarily reflects the substantial completion of certain components of the company’s research obligations under its collaborations.

Epizyme, Inc. to Report Q1, 2015 Results on Apr 28, 2015

Epizyme, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on Apr 28, 2015

Similar Private Companies By Industry

Company Name Region
OrphageniX, Inc. United States
Vitaphore Corporation United States
Advanced Photodynamic Technologies, Inc. United States
RadioPharmacy Investors, LLC United States
Rubisco Corp United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Epizyme, Inc., please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.